Symbiotec Pharmalab Adheres to SEBI Insider Trading Regulations with Updated Disclosure Code
Symbiotec Pharmalab Limited has submitted its updated Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. This action ensures adherence to fair disclosure norms for price-sensitive information.
This is a standard regulatory compliance filing regarding insider trading procedures, which is not expected to have a significant direct impact on the company's operations or stock price.
The announcement is a routine compliance filing related to SEBI regulations and does not contain information that positively or negatively impacts the company's financial performance or market position.
Symbiotec Pharmalab Limited has submitted an intimation regarding its compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. Pursuant to Regulation 8(2) of these regulations, the company has enclosed its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, framed under Regulation 8(1) of the SEBI PIT Regulations.
This disclosure is intended to ensure fair disclosure of unpublished price sensitive information, aligning with regulatory requirements. The company has provided the necessary documentation to the Listing Departments of BSE Limited and the National Stock Exchange of India Limited.
This proactive measure underscores Symbiotec Pharmalab's commitment to transparency and adherence to the SEBI PIT Regulations.
A plain-language summary of a public exchange filing by Symbiotec Pharmalab Limited. Read the original for the full detail.